|
1
|
Levin TR and Corley DA: Colorectal-cancer
screening - coming of age. N Engl J Med. 369:1164–1166. 2013.
|
|
2
|
Mastalier B, Tihon C, Ghiţă B, Botezatu C,
Deaconescu V, Mandisodza P, Drăghici C and Simion S: Surgical
treatment of colon cancer: Colentina surgical clinic experience. J
Med Life. 5:348–353. 2012.
|
|
3
|
Ito Y, Yamada Y, Asada K, Ushijima T,
Iwasa S, Kato K, Hamaguchi T and Shimada Y: EGFR L2 domain mutation
is not correlated with resistance to cetuximab in metastatic
colorectal cancer patients. J Cancer Res Clin Oncol. 139:1391–1396.
2013.
|
|
4
|
Zhu XS, Dai YC, Chen ZX, Xie JP, Zeng W,
Lin YY and Tan QH: Knockdown of ECHS1 protein expression inhibits
hepatocellular carcinoma cell proliferation via suppression of Akt
activity. Crit Rev Eukaryot Gene Expr. 23:275–282. 2013.
|
|
5
|
Lin YL and Pasero P: Interference between
DNA replication and transcription as a cause of genomic
instability. Curr Genomics. 13:65–73. 2012.
|
|
6
|
Magge D, Zureikat AH, Bartlett DL,
Holtzman MP, Choudry HA, Beumer JH, Pingpank JF, Holleran JL,
Strychor S, Cunningham DE, et al: A phase I trial of isolated
hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with
unresectable isolated liver metastases from colorectal cancer. Ann
Surg Oncol. 20:2180–2187. 2013.
|
|
7
|
Mirakhorli M, Rahman SA, Abdullah S,
Vakili M, Rozafzon R and Khoshzaban A: Multidrug resistance protein
2 genetic polymorphism and colorectal cancer recurrence in patients
receiving adjuvant FOLFOX-4 chemotherapy. Mol Med Rep. 7:613–617.
2013.
|
|
8
|
Sharp TV, Munoz F, Bourboulia D, Presneau
N, Darai E, Wang HW, Cannon M, Butcher DN, Nicholson AG, Klein G,
et al: LIM domains-containing protein 1 (LIMD1), a tumor suppressor
encoded at chromosome 3p21.3, binds pRB and represses E2F-driven
transcription. Proc Natl Acad Sci USA. 101:16531–16536. 2004.
|
|
9
|
Xu K, Liang X, Shen K, Sun L, Cui D, Zhao
Y, Tian J, Ni L and Liu J: MiR-222 modulates multidrug resistance
in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell
Res. 318:2168–2177. 2012.
|
|
10
|
Maddalena F, Laudiero G, Piscazzi A,
Secondo A, Scorziello A, Lombardi V, Matassa DS, Fersini A, Neri V,
Esposito F and Landriscina M: Sorcin induces a drug-resistant
phenotype in human colorectal cancer by modulating Ca(2+)
homeostasis. Cancer Res. 71:7659–7669. 2011.
|
|
11
|
Andersen V, Ostergaard M, Christensen J,
Overvad K, Tjønneland A and Vogel U: Polymorphisms in the
xenobiotic transporter Multidrug Resistance 1 (MDR1) and
interaction with meat intake in relation to risk of colorectal
cancer in a Danish prospective case-cohort study. BMC Cancer.
9:4072009.
|
|
12
|
Andersen V, Agerstjerne L, Jensen D,
Østergaard M, Saebø M, Hamfjord J, Kure E and Vogel U: The
multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is
not associated with disease susceptibility in Norwegian patients
with colorectal adenoma and colorectal cancer; a case control
study. BMC Med Genet. 10:182009.
|
|
13
|
Vilaça N, Amorim R, Machado AF, Parpot P,
Pereira MF, Sardo M, Rocha J, Fonseca AM, Neves IC and Baltazar F:
Potentiation of 5-fluorouracil encapsulated in zeolites as drug
delivery systems for in vitro models of colorectal carcinoma.
Colloids Surf B Biointerfaces. 112:237–244. 2013.
|
